11:15:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-11-21 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-28 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning LPGO 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-30 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning LPGO 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-19 Extra Bolagsstämma 2022
2022-05-03 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1


ListaFirst North Stockholm
Lipigon Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling av diverse läkemedelskandidater. Produktportföljen är bred och inkluderar läkemedel för sällsynta sjukdomar. Detta är främst behandlingar för sjukdomar orsakade av rubbningar i kroppens hantering av fetter. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden.
2023-06-08 10:40:59

Lipigon Pharmaceuticals (Lipigon) today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application covering Lipisense for the treatment of cardiometabolic disease.

According to the plan, Lipigon has received a Notice of Allowance, which means that the USPTO intends to grant the patent after completing certain formal steps. Once granted, the patent will be valid until 2039.

Lipigon's patent application 17/667,449 in the USA protects the use of antisense oligonucleotides targeting specific sequences of ANGPTL4 mRNA for reducing ANGPTL4 expression as treatment of cardiometabolic diseases, including obesity, diabetes, hypercholesterolemia, hypertriglyceridemia (HTG), dyslipidemia, pancreatitis, metabolic syndrome, and familial chylomicronemia syndrome (FCS).

"This is an important step for Lipigon in the process of protecting the intellectual property rights of the Lipisense program. Since the US is the single biggest pharmaceutical market, this is strategically important for the company," says CEO Dr. Stefan K Nilsson.

For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: stefan@lipigon.se
Phone: +46 705 78 17 68

The following documents can be retrieved from beQuoted

About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigons initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA-drug Lipisense for the treatment of hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.